April 2011

Baxter International Inc. Acquires Prism Pharmaceuticals

United States - Illinois | United States - Pennsylvania

Baxter International Inc. acquired Prism Pharmaceuticals for $338 million, with Faegre Baker Daniels corporate partner Roger Rhoten advising.

Pennsylvania-based Prism Pharmaceuticals is a specialty pharmaceutical company which recently received FDA approval of an antiarrhythmic drug, enhancing Baxter's portfolio of acute care premix drugs.

The Faegre Baker Daniels website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Baker Daniels' cookies information for more details.